- Home
- CJET vs APRE Comparison
CJET vs APRE Comparison
Compare CJET & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- APRE
- Stock Information
- Founded
- CJET 2009
- APRE 2006
- Country
- CJET China
- APRE United States
- Employees
- CJET N/A
- APRE N/A
- Industry
- CJET Auto Manufacturing
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CJET Consumer Discretionary
- APRE Health Care
- Exchange
- CJET Nasdaq
- APRE Nasdaq
- Market Cap
- CJET 14.3M
- APRE 15.8M
- IPO Year
- CJET N/A
- APRE 2019
- Fundamental
- Price
- CJET $1.76
- APRE $3.85
- Analyst Decision
- CJET
- APRE Strong Buy
- Analyst Count
- CJET 0
- APRE 2
- Target Price
- CJET N/A
- APRE $15.50
- AVG Volume (30 Days)
- CJET 69.5K
- APRE 33.0K
- Earning Date
- CJET 01-28-2025
- APRE 11-07-2024
- Dividend Yield
- CJET N/A
- APRE N/A
- EPS Growth
- CJET N/A
- APRE N/A
- EPS
- CJET N/A
- APRE N/A
- Revenue
- CJET $10,275,000.00
- APRE $1,310,839.00
- Revenue This Year
- CJET N/A
- APRE $134.21
- Revenue Next Year
- CJET N/A
- APRE N/A
- P/E Ratio
- CJET N/A
- APRE N/A
- Revenue Growth
- CJET 31.31
- APRE 130.31
- 52 Week Low
- CJET $1.65
- APRE $2.15
- 52 Week High
- CJET $23.94
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- CJET 37.95
- APRE 56.63
- Support Level
- CJET $1.93
- APRE $3.34
- Resistance Level
- CJET $2.08
- APRE $3.83
- Average True Range (ATR)
- CJET 0.17
- APRE 0.42
- MACD
- CJET -0.06
- APRE 0.01
- Stochastic Oscillator
- CJET 10.71
- APRE 36.04
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.